Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Aramchol in NASH
2019-002073-56Phase 3Unknown
- Sponsor
- Galmed Pharmaceuticals
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Aramchol 300 mg BID with Placebo (2 arms). Primary endpoint: Histology-Based primary endpoint at week 52. Status: unknown.
02
Drugs
aramchol
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-002073-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002073-56.